PT - JOURNAL ARTICLE AU - Alessandra Bettiol AU - Renato Alberto Sinico AU - Franco Schiavon AU - Sara Monti AU - Enrica Paola Bozzolo AU - Franco Franceschini AU - Marcello Govoni AU - Claudio Lunardi AU - Giuseppe Guida AU - Giuseppe Lopalco AU - Giuseppe Paolazzi AU - Angelo Vacca AU - Gina Gregorini AU - Pietro Leccese AU - Matteo Piga AU - Fabrizio Conti AU - Paolo Fraticelli AU - Luca Quartuccio AU - Federico Alberici AU - Carlo Salvarani AU - Silvano Bettio AU - Simone Negrini AU - Carlo Selmi AU - Savino Sciascia AU - Gabriella Moroni AU - Loredana Colla AU - Carlo Manno AU - Maria Letizia Urban AU - Alfredo Vannacci AU - Maria Rosa Pozzi AU - Paolo Fabbrini AU - Stefano Polti AU - Mara Felicetti AU - Maria Rita Marchi AU - Roberto Padoan AU - Paolo Delvino AU - Roberto Caporali AU - Carlomaurizio Montecucco AU - Lorenzo Dagna AU - Adriana Cariddi AU - Paola Toniati AU - Silvia Tamanini AU - Federica Furini AU - Alessandra Bortoluzzi AU - Elisa Tinazzi AU - Lorenzo Delfino AU - Iuliana Badiu AU - Giovanni Rolla AU - Vincenzo Venerito AU - Florenzo Iannone AU - Alvise Berti AU - Roberto Bortolotti AU - Vito Racanelli AU - Guido Jeannin AU - Angela Padula AU - Alberto Cauli AU - Roberta Priori AU - Armando Gabrielli AU - Milena Bond AU - Martina Tedesco AU - Giulia Pazzola AU - Paola Tomietto AU - Marco Pellecchio AU - Chiara Marvisi AU - Federica Maritati AU - Alessandra Palmisano AU - Christian Dejaco AU - Johann Willeit AU - Stefan Kiechl AU - Iacopo Olivotto AU - Peter Willeit AU - Domenico Prisco AU - Augusto Vaglio AU - Giacomo Emmi AU - on behalf of the Italian EGPA Consortium TI - Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) AID - 10.1101/2020.11.09.20228197 DP - 2021 Jan 01 TA - medRxiv PG - 2020.11.09.20228197 4099 - http://medrxiv.org/content/early/2021/01/06/2020.11.09.20228197.short 4100 - http://medrxiv.org/content/early/2021/01/06/2020.11.09.20228197.full AB - Background and objective Systemic small vessel vasculitides carry an increased risk of acute arterial and venous thromboembolic events (AVTE); however, this risk has not been systematically explored in Eosinophilic Granulomatosis with Polyangiitis (EGPA). This study assessed the occurrence and main risk factors of AVTE among EGPA patients as compared to the general community from the population-based Bruneck cohort.Methods We conducted a retrospective multicenter cohort study on 573 EGPA patients. Clinical and serological data were collected at diagnosis. Occurrence of AVTE and time to the first AVTE after EGPA diagnosis were recorded. Age-standardized event rate (SER) of AVTE as compared to the reference cohort was assessed. Cox regression was applied to identify AVTE predictors.Results 129 EGPA patients (22.5%) had AVTE, considered as potentially life-threatening in 55.8%. Seventy patients experienced an AVTE prior to diagnosis (of whom 58.6% in the two years before diagnosis) and 75 following EGPA diagnosis, of whom 56% in the two subsequent years. The SER of AVTE as compared to the reference cohort was 2.10 (95% CI 1.67-2.63). This risk was particularly increased in patients with history of AVTE and with a Birmingham Vasculitis Activity Score ≥20 at diagnosis. Patients receiving immunosuppression within 2 months of diagnosis were at lower risk, while antiplatelet or anticoagulant treatment did not confer measurable benefit.Conclusion EGPA is associated with AVTE in approximately one quarter of patients, particularly around diagnosis. Immunosuppressants seemed to exert a protective effect, while anticoagulant and antiplatelet agents did not.Competing Interest StatementDr. Silvia Tamanini worked at ASST Spedali Civili Brescia, Unit of Rheumatology and Immu-nology at the moment of the study. At the moment of publication, she works at Glaxo Smith Kline. All other authors report no conflicts of interest.Clinical TrialThis is a retrospective observational studyFunding StatementThis study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in compliance with the Declaration of Helsinki and approved by the Ethic Committee of the University Hospital Careggi, Florence, Italy (Approval number 12804/CAM_BIO).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified participant data are available upon reasonable request, to be sent by email to the corresponding author.